お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
979514

クラミジア・トラコマチス検査(体外診断)-世界市場の分析および予測モデル(COVID-19による市場への影響)

Chlamydia Trachomatis Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact)

出版日: | 発行: GlobalData | ページ情報: 英文 | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
クラミジア・トラコマチス検査(体外診断)-世界市場の分析および予測モデル(COVID-19による市場への影響)
出版日: 2020年12月15日
発行: GlobalData
ページ情報: 英文
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートは、2020年以降のクラミジア・トラコマチス検査市場に対するCOVID-19の影響を詳細に説明しています。クラミジア・トラコマチスは、肛門性交、オーラルセックス、または膣性交中に感染する可能性があります。また、出産時に母親から新生児に受け継がれることもあります。この病気は女性と若年成人(15~24歳)によく見られます。

一般に、クラミジア・トラコマチス感染による不妊症に苦しむ男性と女性の数が増加しているため、世界中で行われている人工授精(AI)または子宮内授精(IUI)の数が増えています。クラミジア・トラコマチス検査に関するレポートは、NAAT、マルチパラメータCT / NG NAAT、およびその他のCT検査を対象としています。

当レポートでは、クラミジア・トラコマチス検査市場について調査し、市場の概要とともに、2015~2030年の市場見通し、セグメント別、国別の動向などを提供しています。

  • 主要な業界動向の洞察
  • 2015年~2030年までのセグメント別市場見通し
  • 手技件数、台数、平均販売価格、セグメント別市場価値に関する詳細データ

世界の地域、国別動向

  • 国別分析
  • SWOT分析
  • 競合動向

ヘルスケアシステムの概要

  • ヘルスケア制度の国別概要
  • 国別の償還方針
  • 国固有の医療技術に関する規制動向

網羅された企業:Hologic Inc、Quidel Corp、Zeptrometrix Corporation、Trinity Biotech Plc、Bio-Rad Laboratories、Becton Dickinson、その他

対象国:米国、英国、ドイツ、フランス、イタリア、スペイン、ブラジル、中国、インド、ロシア、日本、オーストラリア、カナダ、メキシコ、韓国、デンマーク、アイルランド、オランダ、ニュージーランド、南アフリカ、スウェーデン、スイス、オーストリア、ベルギー、フィンランド、イスラエル、ノルウェー、ポーランド、ポルトガル、台湾、チェコ共和国、ギリシャ、ハンガリー、トルコ、エジプト、サウジアラビア、アラブ首長国連邦、アルゼンチン、チリ

目次
Product Code: GDME621MM

Chlamydia Trachomatis Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Chlamydia Trachomatis Test market for the year 2020 and beyond. Chlamydia Trachomatis can be transmitted during anal, oral, or vaginal sex. It can also be passed from a mother to her new born child during childbirth. The disease is more common in women and young adults (15-24 years).

In general, the number of Artificial Insemination (AI), or Intrauterine Insemination (IUI), procedures performed globally is growing due to increases in the number of men and women suffering from infertility caused by Chlamydia Trachomatis infection. Chlamydia Trachomatis Test model covers NAATs, Multiparameter CT/NG NAATs and other CT tests.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Chlamydia Trachomatis Test and evolving competitive landscape -

  • Insightful review of the key industry trends.
  • Annualized total Chlamydia Trachomatis Tests market revenue by segment and market outlooks from 2015-2030.
  • Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Chlamydia Trachomatis Tests market.
  • Competitive dynamics insights and trends provided for Chlamydia Trachomatis Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Hologic Inc, Quidel Corp, Zeptrometrix Corporation, Trinity Biotech Plc, Bio-Rad Laboratories, Becton Dickinson and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

  • CMO executives who must have deep understanding of the Chlamydia Trachomatis Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

  • Understand the impact of COVID-19 on Chlamydia Trachomatis Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Chlamydia Trachomatis Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Chlamydia Trachomatis Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Chlamydia Trachomatis Tests market from 2015-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.